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In this brief review, I have highlighted recent advances in several ar-
eas of mitochondrial medicine, including mtDNA-related diseases, 
mendelian mitochondrial encephalomyopathies, and therapy. The 
pathogenic mechanisms of mtDNA mutations, especially those af-
fecting mitochondrial protein synthesis, are still largely unknown. 
The pathogenicity of homoplasmic mtDNA mutations has become 
evident but has also called attention to modifying nuclear genes, 
yet another example of impaired intergenomic signaling. The func-
tional significance of the homoplasmic changes associated with mi-
tochondrial haplogroups has been confirmed. Among the mende-
lian disorders, a new form of “indirect hit” has been described, in 
which the ultimate pathogenesis is toxic damage to the respiratory 
chain. Three therapeutic strategies look promising: (i) allogeneic 
hematopoietic stem cell transplantation in MNGIE (mitochondrial 
neurogastrointestinal encephalomyopathy); (ii) bezafibrate, an ac-
tivator of PGC-1α, has proven effective in animal models of mito-
chondrial myopathy; and (iii) pronucleus transfer into a normal 
oocyte is effective in eliminating maternal transmission of mtDNA, 
thus preventing the appearance of mtDNA-related disorders.
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This paper – as the lecture from which it derives – 
are dedicated to the memory of Eduardo Bonilla (Fig. 1), 
a great myologist and a great friend.
Although  mitochondria  have  multiple  functions,  it 
is fair to say that the most important is the generation 
of energy. In Figure 2, an oversimplified schematic view 
of mitochondrial metabolism, I have highlighted the res-
piratory chain, the “business end” of oxidative metabo-
lism, where ATP is actually produced. One “green view” 
of  mitochondria  is  that  they  approximate  ecologically 
friendly hydrogen engines: the breakfast that you ate this 
morning (derived from sunlight) is metabolized through 
pathways residing mostly outside (glycolysis) or inside 
(β-oxidation) the mitochondria. Electrons generated in 
the Krebs cycle from the oxidation of acetyl-CoA are car-
ried along the four multimeric components of the electron 
transport chain (complexes I-IV) embedded in the inner 
mitochondrial membrane (IMM) and protons are pumped 
from the inside of the IMM (mitochondrial matrix) to the 
intermembrane space (IMS) between the IMM and the 
outer  mitochondrial  membrane  (OMM).  The  resulting 
chemosmotic potential is used to operate the tiniest rotary 
machine, ATP synthase (complex V), where the influx of 
protons back into the matrix makes the rotor (F0) turns 
on the stator (F1) at the respectable speed of 1,000 RPM, 
bringing together ADP and Pi and releasing ATP (1, 2). 
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A recent remarkable achievement in our understand-
ing  of  energy  production  by  the  respiratory  chain  has 
been  the  clarification  of  the  α-helical  structure  of  the 
membrane domain of complex I of E. coli by Leonid 
Sazanov’s  group (3).  The  transfer  of  2  electrons  from 
NADH to quinone is coupled to the transfer of 4 pro-
tons across the IMM, and two mechanisms of coupling 
had  been  proposed,  a  direct,  redox-driven  mechanism 
or  an  indirect,  conformation-driven  mechanism. When 
the electrons reach the quinone moiety, conformational 
changes in complex I subunits (called NuoA/J/K/H) push 
a  long  α-helix  towards  other  transmembrane  subunits 
(NuoL/M/N) in a piston-like action [as aptly described by 
Tomoko Onishi in a News & Views article (4)] thus open-
ing up “trapdoors” through which protons can pass.
Let me consider first recent progress in our understand-
ing of pathogenesis, which unfortunately is still largely 
“terra incognita” both for mitochondrial DNA (mtDNA)- 
and for nuclear DNA (nDNA)-related disorders. 
disorders due to mutations  
in mtdnA
For what concerns mtDNA-related diseases, hetero-
plasmy and the threshold effect still are the best crite-
ria to explain phenotypic variability. The best example 
Figure 2. Schematic and simplified view of mitochondrial metabolism. The spirals depict the reactions of the β-oxidation 
pathway. The red oval highlights the reactions of the respiratory chain.Pathogenesis and treatment of mitochondrial myopathies
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is the NARP (neuropathy, ataxia, retinitis pigmentosa) 
syndrome, first described by Anita Harding in 1990 in 
four maternally related relatives: three adults with sen-
sory  neuropathy,  ataxia,  exercise  intolerance,  retinitis 
pigmentosa, and dementia; and one child with devel-
opmental delay, ataxia, retinitis pigmentosa, and abnor-
mal EEG (5). The relationship between m.8993T > G 
mutation load and clinical severity was documented by 
Tatuch et al., who showed that about 70% heteroplasmy 
in skeletal muscle resulted in an adult-onset syndrome 
corresponding  to  the  acronymic  features  of  NARP 
whereas higher degrees of heteroplasmy (around 90%) 
were accompanied by Leigh syndrome (LS) in infants 
or children (6). 
One would expect that mutations in different mito-
chondrial tRNA genes, affecting – as they all do – mito-
chondrial protein synthesis in toto, should cause a “swamp” 
of largely overlapping symptoms and signs. Contrarywise, 
clinical  experience  shows  that  mutations  in  individual 
tRNA genes are often, though not always, associated with 
specific syndromes. Thus, most patients with MELAS har-
bor  the  m.3243A > G  mutation  in  tRNALeu(UUR) whereas 
most patients with MERRF harbor the m.8344A > G mu-
tation in tRNALys. In addition, single deletions in mtDNA, 
which also impair mitochondrial protein synthesis globally, 
almost invariably cause one of three syndromes, the gener-
alized Kearns-Sayre syndrome (KSS), the muscle-specific 
chronic progressive external ophthalmoplegia (CPEO), or 
the hematopoietic Pearson syndrome (PS) (7). At this time, 
the best explanation for this puzzling phenomenon is a spa-
tial selectivity in the distribution of individual mutations, at 
least in the brain. This concept has been supported by im-
munohistochemical and in situ hybridization studies show-
ing, for example, a predilection of the MELAS mutation 
for subpial arterioles (8, 9), of the MERRF mutation for 
the dentate nucleus of the cerebellum (10), and of single 
mtDNA deletions for the choroid plexus (11). The obvious 
but unanswered next question is what “directs” each muta-
tion to a selected area.
The next area of exciting recent development regards 
homoplasmy. Although the first documented pathogenic 
point  mutation  in  mtDNA  (m.11778G > A  in  the  ND4 
gene) was, in fact, homoplasmic and associated with Leber 
hereditary optic neuropathy (LHON) (12), we have long 
ignored this lesson, to the point of including heteroplasmy 
among the canonical criteria of pathogenicity. And this in 
the face of increasing evidence that homoplasmic mutations 
were often associated with tissue-selective disorders such 
as LHON (13), deafness (14), deafness/cardiopathy (15), 
or tissue-specific disorders such as cardiomyopathy (16).
The evolving concept of homoplasmy has resonated 
with me personally because it has solved a conundrum 
that has been a thorn in my side for the past 26 years. 
In 1983, together with my colleagues at Columbia Uni-
versity Medical Center, I reported the puzzling case of 
an infant who was profoundly floppy at birth and whose 
initial  muscle  biopsy  showed  virtually  no  staining  for 
cytochrome c oxidase (COX) (17). With vigorous sup-
portive therapy and despite our gloomy expectations, the 
child improved spontaneously and rather rapidly: his se-
vere lactic acidosis declined, his strength increased, and 
his muscle biopsy at 7 months of age showed that about 
50% of all fibers were now COX-positive. By 3 years 
of age, the child was neurologically normal and a third 
muscle biopsy showed, if anything, some excess COX 
stain. Unfortunately at the time we did not pay enough 
attention to Eduardo Bonilla’s astute observation that the 
mother’s muscle biopsy (but not the father’s) showed a 
few scattered COX-negative fibers. However, it did not 
escape Rita Horvath’s attention that all 17 patients from 
12 unrelated families with virtually identical reversible 
COX-deficient myopathy harbored a homoplasmic “poly-
morphism,” m.14674T > C in the tRNAGlu gene of mtD-
NA (18). This obviously pathogenic change cannot, in 
and by itself, explain the muscle-specificity of the disease 
or its reversibility, nor can it explain why some but not all 
maternal relatives are affected (18). 
Pathogenic  homoplasmic  mtDNA  mutations  high-
light yet another important aspect of the dependence of 
the mitochondrial on the nuclear genome. If it is true that 
from the beginning of mitochondrial genetics there has 
been a lot of handwaving about nuclear factors modulat-
ing the phenotypic expression of mtDNA mutations, now 
this has become a present and immediate question de-
manding that we identify the putative “nuclear modifiers” 
and understand their mechanism of action.
In the long course of their migration out of Africa, 
which started about 150,000 year ago, our ancestors accu-
mulated harmless mtDNA changes (polymorphisms) that 
differed among different populations and still define eth-
nic groups (19). It was proposed that these ancient vari-
ations are not only harmless but, in fact, adaptive, thus 
facilitating the settlement of different groups in favora-
ble ecological niches (20). Thus, for example, a mtDNA 
variation conducive to loose coupling of oxidative phos-
phorylation (OXPHOS) would enhance the dissipation of 
energy as heat and be advantageous to people living in 
frigid climates. Although their effect on OXPHOS would 
be small, haplogroup-defining mutations might behave 
as susceptibility factors in multifactorial diseases, in the 
context  of  particular  environmental  or  nuclear  factors. 
Such small effect on OXPHOS has been documented by 
“homogenizing” environmental and nuclear backgrounds 
with the use of cybrid cell lines, that is, immortalized hu-
man cell lines emptied of their own mtDNA and repopu-
lated with haplotype-specific mitochondria (19). S. DiMauro
336
Mendelian mitochondrial disorders
With the term “indirect hits” we refer to mutations in 
nuclear genes that do not affect respiratory chain subunits 
directly,  but  alter  proteins  needed  for  the  assembly  and 
maintenance  of  respiratory  chain  complexes.  Numerous 
such indirect hits have been associated with defects in all 
five complexes of the respiratory chain (21), but Valeria Ti-
ranti and Massimo Zeviani in Milan, Italy, have discovered 
a novel type of indirect hit, where the second whammy is 
toxic instead of structural. First, using integrative genom-
ics, they found that ethylmalonic encephalomyopathy (EE), 
a  devastating  early-onset  disorder  with  encephalopathy, 
microangiopathy, chronic diarrhea, and massively increased 
levels of ethylmalonic acid and short-chain acylcarnitines in 
body fluids, was due to mutations in the ETHE1 gene (22). 
They  then  documented  that  ETHE1  is  a  mitochondrial 
matrix thioesterase (23) and created an Ethe1-null mouse, 
which led them to discover that thiosulfate and sulfide accu-
mulate excessively both in the animal model and in affected 
children due to the lack of sulfur dioxygenase activity (24). 
As sulfide is a powerful COX inhibitor, what they described 
was an indirect hit of a toxic kind and likely the prototype 
of other similar pathogenic mechanisms.
Yet another indirect mechanism involving sulfur me-
tabolism (the mitochondrial disulfide relay system, DRS) 
and resulting in multiple respiratory chain enzyme deficien-
cies (complexes I, II, and IV) was discovered by the group 
of Giacomo Comi, also in Milan (25). The patients were 
three siblings born of consanguineous parents. They all had 
congenital cataracts and various degrees of psychomotor 
delay, hypotonia, hearing loss, bilateral or unilateral ptosis, 
sensorineural hearing loss, and lactic acidosis. At age 17 
years, the older sibling needed tutorial assistance at school 
and was hyporeflexic. His brain MRI only showed thinning 
of  the  corpus  callosum.  Muscle  histochemistry  showed 
scattered COX-negative, SDH-hyperintense fibers and ul-
trastructural studies revealed vacuolated mitochondria with 
thickened cristae. Biochemical analysis showed partial de-
crease of COX (30%-50% residual activity) and less severe 
reduction of complexes I and II. Homozygosity mapping 
led to the identification of a missense mutation in the gene 
(GFER) whose product belongs to the ERV1/ALR protein 
family. Yeast Erv1p (and presumably its human counterpart 
GFER,  a  sulfhydryl  oxidase)  oxidizes  the  disulfide  car-
rier protein Mia40, which, in turn, transfers a disulfide to 
newly synthesized proteins in the mitochondrial IMS. The 
reoxidaton of Erv1p is mediated by cytochrome c and COX, 
thus linking the DRS to the mitochondrial respiratory chain. 
Comi and coworkers showed that the mutant GFER is un-
stable and its concentration decreases in mitochondria, thus 
probably inhibiting the import of DRS substrates, including 
COX17, TIMM13, and COX6B1 (25). It is noteworthy that 
a mutation in COX6B1 has been the first example of a “di-
rect hit” in complex IV deficiency (26). It is also notewor-
thy that defects of the DRS are yet another cause of multiple 
mtDNA deletions, which were documented in muscle from 
one of the patients with mutant GFER (25). 
As I mentioned in a recent historical review (21) for 
now at least, the last frontier of research in mitochondrial 
disorders seems to be the defects of mitochondrial transla-
tion. Within the past four years, often through homozygosity 
mapping, defects have been discovered in genes controlling 
factors at all levels of the complex translation apparatus, from 
rRNA base modification, such as MRPS16 (27) to general 
translation, such as EFG1 (now called GFM1) (28-31) to 
tRNA processing and base modification, such as PUS1 (32) 
to tRNA synthetase (33, 34). This subject has been recently 
and lucidly reviewed by Smits et al. (35). 
therapy
This is very much an area of work in progress, but there 
are three developments that are worth discussing briefly: 
stem cell therapy in mitochondrial neurogastrointestinal 
encephalomyopathy  (MNGIE);  boosting  mitochondrial 
biogenesis as a therapeutic strategy; and pronuclear trans-
fer as a preventive measure to mtDNA-related disorders.
MNGIE is an autosomal recessive multisystemic dis-
ease characterized clinically by progressive external oph-
thalmoplegia  (PEO),  ptosis,  gastrointestinal  dysmotility, 
extreme  cachexia,  peripheral  neuropathy,  leukoencepha-
lopathy, and death in early or mid-adulthood (36). The dis-
ease is due to loss-of-function mutations in the TYMP gene 
that encodes the cytosolic enzyme thymidine phosphory-
lase (TPase) (37). As a result, there is a dramatic elevation 
of thymidine and deoxyuridine in blood and tissues (38) 
and severe deoxynucleotide pool imbalance, which causes 
multiple  mtDNA  deletions,  depletion,  and  site-specific 
point  mutations (39).  One  obvious  therapeutic  approach 
is to eliminate the toxic metabolites through hemodialysis, 
but single treatments had only transient effect in two pa-
tients (40) whereas chronic dialysis for over a year failed to 
slow disease progression in one patient (41). Nor did pro-
longed peritoneal dialysis fare any better (42). Attempts to 
replace the missing TPase using erythrocyte-encapsulated 
TPase or platelet infusion did improve symptoms but para-
doxically did not lower plasma nucleotide levels (42). 
Michio Hirano took a more radical approach to en-
zyme replacement therapy by employing allogeneic he-
matopoietic  stem  cell  transplantation  (HSCT),  which 
proved very effective in a first patient (43, 44) and has 
been successful to date in five of the 11 patients so treat-
ed (45). An international therapeutic trial is underway and 
will hopefully confirm that this approach, though risky, 
can be a lifesaver in MNGIE.Pathogenesis and treatment of mitochondrial myopathies
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In recent years, increasing attention has been directed 
to mitochondrial biogenesis and, more specifically, to the 
peroxisome proliferator-activated receptor γ coactivator-1α 
protein (PGC-1α for short), a transcriptional coactivator 
that binds to several transcription factors and induces gene 
expression (46). Importantly, PGC-1α is a strong promoter 
of mitochondrial biogenesis and function (47). This prop-
erty has been exploited by French clinical scientists, who 
used bezafibrate (a PGC-1α activator), an approved drug 
in Europe, to treat patients with imborn errors of fatty acid 
oxidation (48, 49) and respiratory chain defects (50). 
In a series of elegant papers, Tina Wenz and Carlos 
Moraes in Miami illustrated both the pathogenic role of 
PGC-1α and its potential therapeutic usefulness. Particular-
ly relevant to the therapy of human mitochondrial myopa-
thies, they used a knock-in mouse model of mitochondrial 
myopathy with partial COX deficiency due to a mutation in 
the assembly gene COX10. Promoting mitochondrial bio-
genesis either by transgenic expression of PG1-α or by ad-
ministration of bezafibrate resulted in improved respiratory 
chain function and ATP production, delayed appearance of 
the myopathy, and prolonged lifespan (51, 52). 
There is a form of gene therapy for mtDNA-related 
diseases that is ready for experimentation in humans but is 
stalled by ethical concerns. Pathogenic mtDNA mutations, 
especially those affecting tRNA genes can be eliminated 
literally ab ovo by transferring an in vitro-fertilized nucleus 
from the ooplasm of a woman carrying the mutation to an 
enucleated oocyte from a normal donor. The resulting em-
bryo, containing normal nuclei from mother and father and 
normal mitochondrial genomes from the donor woman, 
can be implanted in the mother’s uterus. The feasibility 
of cytoplasmic transfer has now been documented by the 
Newcastle group in the UK (53) and a variant of this ap-
proach has been used in the US to produce two healthy 
“transmitochondrial” rhesus monkeys carrying undetect-
able mtDNA from their biological mother (54). 
I hope that this brief update on the pathogenesis and 
therapy of mitochondrial diseases conveys the fervor of 
research in mitochondrial medicine and the exciting reali-
zation that effective therapy is finally within our grasp for 
at least some of these devastating disorders.
Acknowledgements
Part of the work described here is supported by NIH 
grant HD32062 and by the Marriott Mitochondrial Disor-
der Clinical Research Fund (MMDCRF).
Abbreviations
ADP, adenosine diphosphate; ATP, adenosine triphos-
phate; ANT, adenine nucleotide translocator; CACT, car-
nitine-acyl-carnitine translocase, CoQ, coenzyme Q; CPT, 
carnitine palmitoyltransferase; DIC, dicarboxylate carrier; 
ETF, electron-transfer flavoprotein; ETFDH, ETF dehy-
drogenase; FAD, flavin adenine dinucleotide; FADH2, re-
duced FAD; NADH, reduced nicotinamide adenine dinu-
cleotide; PDHC, pyruvate dehydrogenase complex; TCA, 
tricarboxylic acid; I, complex I; II, complex II; III, complex 
III; IV, complex IV; V, complex V. Modified from 55
references
1.  Boyer PD. A research journey with ATP synthase. J Biol Chem 
2002;277:39045-61.
2.  Stock D, Gibbons C, Arechaga I, et al. The rotary mechanism of 
ATP synthase. Curr Opin Struct Biol 2000;10:672-9.
3.  Efremov RG, Baradaran R, Sazanov LA. The architecture of respi-
ratory complex I. Nature 2010;465:441-5.
4.  Ohnishi T. Piston drives a proton pump. Nature 2010;465:428-9.
5.  Holt IJ, Harding AE, Petty RK, et al. A new mitochondrial disease 
associated  with  mitochondrial  DNA  heteroplasmy.  Am  J  Hum 
Genet 1990;46:428-33.
6.  Tatuch Y, Christodoulou J, Feigenbaum A, et al. Heteroplasmic mtDNA 
mutation (T > G) at 8993 can cause Leigh disease when the percentage 
of abnormal mtDNA is high. Am J Hum Genet 1992;50:852-8.
7.  DiMauro S, Davidzon, G. Mitochondrial DNA and disease. Ann 
Med 2005;37:222-32.
8.  Tanji K, Kunimatsu T, Vu TH, et al. Neuropathological features of 
mitochondrial disorders. Cell Develop Biol 2001;12:429-39.
9.  Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of 
MELAS: level of heteroplasmy in individual meurones and evi-
dence of extensive vascular involvement. Neuropathol Appl Neu-
robiol 2006;32:359-73.
10.  Sparaco M, Schon EA, DiMauro S, et al. Myoclonic epilepsy with 
ragged-red fibers (MERRF): an immunohistochemical study of the 
brain. Brain Pathol 1995;5:125-33.
11.  Tanji K, Schon EA, DiMauro S, et al. Kearns-Sayre syndrome: on-
cocytic transformation of choroid plexus epithelium. J Neurol Sci 
2000;178;29-36.
12.  Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA muta-
tion associated with Leber’s hereditary optic neuropathy. Science 
1988;242:1427-30.
13.  Carelli V, Barboni P, Sadun AA. Mitochondrial ophthalmology. In: 
DiMauro S, Hirano M, Schon EA, eds. Mitochondrial Medicine. 
London: Informa Healthcare 2006, pp. 105-142.
14.  Li X, Zhang LS, Fischel-Ghodsian N, et al. Biochemical characteri-
zation  of  the  deafness-associated  mitochondrial  tRNASer(UCN) 
A7445G mutation in osteosarcoma cell cybrids. Biochem Biophys 
Res Comm 2005;328:491-8.
15.  Santorelli FM, Tanji K, Manta P, et al. Maternally inherited car-
diomyopathy: an atypical presentation of the 12S rRNA A1555G 
mutation. Am J Hum Genet 1999;64:295-300.
16.  Taylor RW, Giordano C, Davidson MM, et al. A homoplasmic mito-
chondrial transfer ribonucleic acid mutation as a cause of maternally 
inherited cardiomyopathy. J Am Coll Cardiol 2003;41:1786-96.
17.  DiMauro S, Nicholson JF, Hays AP, et al. Benign infantile mito-
chondrial myopathy due to reversible cytochrome c oxidase defi-
ciency. Ann Neurol 1983;14:226-34.
18.  Horvath R, Kemp JP, Tuppen HA, et al. Molecular basis of infantile 
reversible cytochrome c oxidase deficiency. Brain 2009;132:3165-74.S. DiMauro
338
19.  Gomez-Duran A, Pacheu-Grau D, López-Gallardo E, et al. Un-
masking  the  causes  of  multifactorial  disorders:  OXPHOS  dif-
ferences  between  mitochondrial  haplogroups.  Hum  Mol  Genet 
2010;19:3343-53.
20.  Wallace DC. The mitochondrial genome in human adaptive radia-
tion and disease: on the road to therapeutics and performance en-
hancement. Gene 2005;354:169-80.
21.  DiMauro S. A history of mitochondrial diseases. J Inher Metab Dis 
2010, DOI 10.1007/s10545-010-9082-x.
22.  Tiranti V, D’Adamo P, Briem E, et al. Ethylmalonic encephalopathy 
is caused by mutations in ETHE1, a gene encoding a mitochondrial 
matrix protein. Am J Hum Genet 2004;74:239-52.
23.  Tiranti V, Briem E, Lamantea E, et al. ETHE1 mutations are spe-
cific to ethylmalonic encephalopathy. J Med Genet 2006;43:340-6.
24.  Tiranti V, Viscomi C, Hildebrandt T, et al. Loss of ETHE1, a mito-
chondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic 
encephalopathy. Nature Med 2009;15:200-5.
25.  Di Fonzo A, Ronchi D, Lodi T, et al. The mitochondrial disulfide 
relay system protein GFERis mutated in autosomal-recessive my-
opathy with cataract and combined respiratory-chain deficiency. 
Am J Hum Genet 2009;84:594-604.
26.  Massa V, Fernandez-Vizarra E, Alshahwan S, et al. Severe infan-
tile encephalomyopathy caused by a mutation in COX6B1, a nu-
cleus-encoded subunit of cytochrome c oxidase. Am J Hum Genet 
2008;82:1281-9.
27.  Miller C, Saada A, Shaul N, et al. Defective mitochondrial transla-
tion caused by a ribosomal protein (MRPS16) mutation. Ann Neu-
rol 2004;56:734-8.
28.  Antonicka H, Sasarman F, Kennaway NG, et al. The molecular 
basis for tissue specificity of the oxidative phosphorylation defi-
ciencies in patients with mutations in the mitochondrial translation 
factor EFG1. Hum Mol Genet 2006;15:1835-46.
29.  Coenen MJH, Antonicka H, Ugalde C, et al. Mutant mitochondrial 
elongation factor G1 and combined oxidative phosphorylation defi-
ciency. N Engl J Med 2004;351:2080-6.
30.  Smeitink JAM, Elpeleg O, Antonicka H, et al. Distinct clinical phe-
notypes associated with a mutation in the mitochondrial translation 
elongation factor EFTs. Am J Hum Genet 2006;79:869-77.
31.  Valente L, Tiranti V, Marsano RM, et al. Infantile encephalopathy 
and defective mitochondrial DNA translation in patients with muta-
tions of mitochondrial elongation factors EGF1 and EFTu. Am J 
Hum Genet 2007;80:44-58.
32.  Bykhovskaya Y, Casas KA, Mengesha E, et al. Missense muta-
tion  in  pseudouridine  synthase  1  (PUS1)  causes  mitochondrial 
myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 
2004;74:1303-8.
33.  Scheper GC, an der Klok T, van Andel RJ, et al. Mitochondrial 
aspartyl-tRNA synthetase deficiency causes leukoencephalopathy 
with brain stem and spinal cord involvement and lactate elevation. 
Nature Genet 2007;39:534-8.
34.  Edvardson S, Shaag A, Kolesnikova O, et al. Deleterious muta-
tion  in  the  mitochondrial  arginyl-transfer  RNA  synthetase  gene 
is associated with pontocerebellar hypoplasia. Am J Hum Genet 
2007;81:857-62.
35.  Smits P, Smeitink JAM, van den Heuvel B. Mitochondrial trans-
lation  and  beyond;  Processes  implicated  in  combined  oxida-
tive  phosphorylation  deficiencies.  J  Biomed  Biotechnol  2010, 
doi:1155/2010/737385.
36.  Hirano M, Nishigaki Y, Marti R. Mitochondrial Neurogastrintes-
tinal Encephalomyopathy (MNGIE): a disease of two genomes. 
Neurologist 2004;10:8-17.
37.  Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene 
mutations in MNGIE, a human mitochondrial disorder. Science 
1999;283:689-92.
38.  Valentino  ML,  Martí  R,  Tadesse  S,  et  al.  Thymidine  and  de-
oxyuridine accumulate in tissues of patients with mitochondrial 
neurogastrintestinal  encephalomyopathy  (MNGIE).  FEBS  Lett 
2007;581:3410-4.
39.  Lopez  LC, Akman  HO,  García-Cazorla A,  et  al.  Umbalanced 
deoxynucleotide  pools  cause  mitochondrial  DNA  instabil-
ity in thymidine phosphorylase-deficient mice. Hum Mol Genet 
2009;18:714-22.
40.  Spinazzola A, Marti R, Nishino I, et al. Altered thymidine me-
tabolism due to defects of thymidine phosphorylase. J Biol Chem 
2002;277:4128-32.
41.  la Marca G, Malvagia S, Casetta B, et al. Pre- and post-dialy-
sis quantitative dosage of thymidine in urine and plasma of a 
MNGIE patient by using HPLC-ESI-MS/MS. J Mass Spectrom 
2006;41:586-92.
42.  Yavuz H, Ozel A, Christensen M, et al. Treatment of mitochondrial 
neurogastrointestinal encephalomyopathy with dialysis. Arch Neu-
rol 2007;64:435-8.
43.  Hirano M, Martí R, Casali C, et al. Allogeneic stem cell transplan-
tation corrects biochemical derangements in MNGIE. Neurology 
2006;67:1458-60.
44.  Schon EA, DiMauro S, Hirano M, et al. Therapeutic prospects for 
mitochondrial disease. Trends Mol Med 2010;16:268-76.
45.  Schupbach M, Benoist J-F, Casali C,  et al. Allogeneic hemat-
opoietic  stem  cell  transplantation  (HSCT)  for  mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE). Neurology 
2009;73:332.
46.  Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1-
alpha drives the formation of slow-twitch muscle fibers. Nature 
2002;418:797-801.
47.  Rohas LM, St-Pierre J, Uldry M, et al. A fundamental system of 
cellular energy homeostasis regulated by PGC-1alpha. Proc Natl 
Acad Sci USA 2007;104:7933-8.
48.  Djouadi F, Bastin J. PPARs as therapeutic targets for correction of 
inborn mitochondrial fatty acid oxidation disorders. J Inher Metab 
Dis 2008;31:217-25.
49.  Gobin-Limballe S, Djouadi F, Aubey F, et al. Genetic basis for cor-
rection of very-long-chain acyl-coenzyme A dehydrogenase by be-
zafibrate in patients fibroblasts: towards a genotype-based therapy. 
Am J Hum Genet 2007;81:1133-43.
50.  Bastin J, Aubey F, Rotig A, et al. Activation of peroxisome prolif-
erator-activated receptor pathway stimulates the mitochondrial res-
piratory chain and can correct deficiencies in patients’ cells lacking 
its components. J Clin Endocrinol Metab 2008;93:1433-41.
51.  Wenz T,  Diaz  F,  Spiegelman  BM,  et  al.  C.T. Activation  of  the 
PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and ef-
fectively improves a mitochondrial myopathy phenotype. Cell Me-
tab 2008;8:249-55.
52.  Wenz T. PGC-1alpha activation asa therapeutic approach in mito-
chondrial disease. IUBMB Life 2009;61:1051-62.
53.  Craven L, Tuppen HA, Greggains GD, et al. Pronuclear transfer 
in human embryos to prevent transmission of mitochondrial DNA 
disease. Nature 2010; 465:82-5.
54.  Tachibana M, Sparman M, Sritanaudomchai H, et al. Mitochondrial 
gene replacement in primate offspring and embryonic stem cells. 
Nature 2009;461:367-72.
55.  DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. 
N Engl J Med 2003;348:2656-68.